WO2012129488A3 - Gene signatures associated with rejection or recurrence of cancer - Google Patents

Gene signatures associated with rejection or recurrence of cancer Download PDF

Info

Publication number
WO2012129488A3
WO2012129488A3 PCT/US2012/030312 US2012030312W WO2012129488A3 WO 2012129488 A3 WO2012129488 A3 WO 2012129488A3 US 2012030312 W US2012030312 W US 2012030312W WO 2012129488 A3 WO2012129488 A3 WO 2012129488A3
Authority
WO
WIPO (PCT)
Prior art keywords
recurrence
cancer
tools
methods
rejection
Prior art date
Application number
PCT/US2012/030312
Other languages
French (fr)
Other versions
WO2012129488A2 (en
Inventor
Masoud H. Manjili
Maciej Kmieciak
Amir A. TOOR
Michael O. Idowu
Harry D. Bear
Kyle K. PAYNE
Francesco M. Marincola
Ena Wang
Original Assignee
Virginia Commonwealth University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Commonwealth University filed Critical Virginia Commonwealth University
Publication of WO2012129488A2 publication Critical patent/WO2012129488A2/en
Publication of WO2012129488A3 publication Critical patent/WO2012129488A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Methods and tools for assessing the prognosis for patients following treatment of primary tumors are provided. The methods involve identifying immune- or cancer-related genetic markers whose differential expression patterns at tumor lesions are indicative of either tumor recurrence or recurrence-free survival. The methods and tools of the invention assist physicians by providing objective decision-making tools for planning patient treatment protocols.
PCT/US2012/030312 2011-03-23 2012-03-23 Gene signatures associated with rejection or recurrence of cancer WO2012129488A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161466615P 2011-03-23 2011-03-23
US61/466,615 2011-03-23
US201161537130P 2011-09-21 2011-09-21
US61/537,130 2011-09-21

Publications (2)

Publication Number Publication Date
WO2012129488A2 WO2012129488A2 (en) 2012-09-27
WO2012129488A3 true WO2012129488A3 (en) 2012-12-27

Family

ID=46880064

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/030312 WO2012129488A2 (en) 2011-03-23 2012-03-23 Gene signatures associated with rejection or recurrence of cancer

Country Status (1)

Country Link
WO (1) WO2012129488A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3295951T (en) 2015-02-19 2020-07-21 Compugen Ltd Anti-pvrig antibodies and methods of use
WO2016134335A2 (en) 2015-02-19 2016-08-25 Compugen Ltd. Pvrig polypeptides and methods of treatment
EP3115784A1 (en) * 2015-07-10 2017-01-11 Koss, Michael Janusz Polypeptide marker for analysis, diagnosis and therapy of eye-related diseases
AU2017313405B2 (en) 2016-08-17 2024-09-26 Compugen Ltd. Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
EP3516076A1 (en) * 2016-09-19 2019-07-31 Institut Gustave-Roussy Nox2 as a biomarker of radiotherapy efficiency in cancer patients
KR20200021474A (en) 2017-06-01 2020-02-28 컴퓨젠 엘티디. Triple Combination Antibody Therapeutics
EP3797173A2 (en) * 2018-05-21 2021-03-31 Nanostring Technologies, Inc. Molecular gene signatures and methods of using same
CN109085363A (en) * 2018-07-26 2018-12-25 苏州呼呼健康科技有限公司 Detection reagent, detection kit and the application and detection method of AKAP4 antigen detection
US20220162705A1 (en) * 2018-11-30 2022-05-26 Gbg Forschungs Gmbh Method for predicting the response to cancer immunotherapy in cancer patients
US20230184771A1 (en) * 2020-04-21 2023-06-15 Board Of Regents, The University Of Texas System Methods for treating bladder cancer
EP4370713A1 (en) 2021-07-15 2024-05-22 Vib Vzw Biomarkers predicting response of breast cancer to immunotherapy
WO2024159070A1 (en) * 2023-01-26 2024-08-02 Mayo Foundation For Medical Education And Research Assessing and treating mammals having polyps

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060115832A1 (en) * 2002-11-14 2006-06-01 Jon Wayne Cancer Institute Detection of cancer cells in body fluids
US20090130678A1 (en) * 2005-12-03 2009-05-21 Siemens Medical Solutions Diagnostics Gmbh Methods and Kits for Breast Cancer Prognosis
WO2010003771A1 (en) * 2008-06-16 2010-01-14 Siemens Healthcare Diagnostics Gmbh Molecular markers for cancer prognosis
US20100280105A1 (en) * 2007-09-17 2010-11-04 Oncomethylome Sciences Sa Detection of mage-a expression
US20110034347A1 (en) * 2008-02-22 2011-02-10 Masoud Manjili Signatures Associated with Rejection or Recurrence of Cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060115832A1 (en) * 2002-11-14 2006-06-01 Jon Wayne Cancer Institute Detection of cancer cells in body fluids
US20090130678A1 (en) * 2005-12-03 2009-05-21 Siemens Medical Solutions Diagnostics Gmbh Methods and Kits for Breast Cancer Prognosis
US20100280105A1 (en) * 2007-09-17 2010-11-04 Oncomethylome Sciences Sa Detection of mage-a expression
US20110034347A1 (en) * 2008-02-22 2011-02-10 Masoud Manjili Signatures Associated with Rejection or Recurrence of Cancer
WO2010003771A1 (en) * 2008-06-16 2010-01-14 Siemens Healthcare Diagnostics Gmbh Molecular markers for cancer prognosis

Also Published As

Publication number Publication date
WO2012129488A2 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
WO2012129488A3 (en) Gene signatures associated with rejection or recurrence of cancer
WO2012153187A3 (en) Markers for cancer prognosis and therapy and methods of use
MX2013008367A (en) Colon cancer gene expression signatures and methods of use.
WO2013182912A3 (en) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
EP2611941A4 (en) Gene signatures for cancer diagnosis and prognosis
WO2008117314A3 (en) Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
CA2840149C (en) Methods and nucleic acids for determining the prognosis of a cancer subject
MX2018009804A (en) High-throughput identification of patient-specific neoepitopes as therapeutic targets for cancer immunotherapies.
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
MX2013002084A (en) Biomarkers and methods of treatment.
WO2014036387A3 (en) Methods for diagnosis and treatment of cancer
WO2007084992A3 (en) Prognosis and therapy predictive markers and methods of use
WO2014057357A3 (en) Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf
WO2010051314A3 (en) Genomic classification of non-small cell lung carcinoma based on patterns of gene copy number alterations
WO2012068383A3 (en) ncRNA AND USES THEREOF
WO2010120942A3 (en) Histone modification patterns for clinical diagnosis and prognosis of cancer
WO2011153545A3 (en) Gene expression signature as a predictor of chemotherapeutic response in breast cancer
MX2013000502A (en) Methods and kits for the diagnosis of prostate cancer.
WO2012125712A3 (en) Lung tumor classifier for current and former smokers
WO2008037700A3 (en) Methods for breast cancer prognosis
WO2016145308A3 (en) Whole blood based mrna markers for predicting prostate cancer and methods of detecting the same
WO2010054397A3 (en) N-cadherin: target for cancer diagnosis and therapy
WO2007002746A3 (en) Molecular/genetic aberrations in surgical margins of resected pancreatic cancer represents neoplastic disease that correlates with disease outcome
WO2013081645A3 (en) Erbb3 mutations in cancer
SG179129A1 (en) Method for identifying whether a patient will be responder or not to immunotherapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12761270

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12761270

Country of ref document: EP

Kind code of ref document: A2